In addition, the BMI1 RNA transcript can be targeted directly; molecules targeting the transcript have shown promising therapeutic potential in reducing the oncogenic potential of prostate CSCs [239] and hepatocellular carcinoma and liver CSCs [240]. This evidence concerns the gene BMI1 and hepatocellular carcinoma.